Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Principal Investigator
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents.
Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic. Clin Adv Hematol Oncol. 2020 07; 18(7):400-403.
View in:
PubMed
subject areas
Betacoronavirus
CD4-Positive T-Lymphocytes
Coronavirus Infections
Cytotoxicity, Immunologic
Gene Expression
Hematologic Neoplasms
Humans
Immunotherapy, Adoptive
Lymphocyte Activation
Pandemics
Pneumonia, Viral
Receptors, Antigen, T-Cell
Severity of Illness Index
T-Lymphocytes, Cytotoxic
authors with profiles
Michael Bishop